Advertisement

Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care

  • Heidi J. Gray
    Correspondence
    Corresponding author at: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, PO Box 356460, University of Washington, Seattle, WA 98195, United States of America.
    Affiliations
    Division of Gynecologic Oncology, Department of OB/GYN, University of Washington, Seattle, WA, United States of America
    Search for articles by this author
  • Angeles Alvarez Secord
    Affiliations
    Division of Gynecologic Oncology, Department of OB/GYN, Duke Cancer Institute, Duke University Health System, Durham, NC, United States of America
    Search for articles by this author
      The Society of Gynecologic Oncology (SGO) 2021 Annual Meeting from March 19–26, 2021 was the first fully virtual meeting and allowed for novel interactive research presentations from around the world. The virtual platform provided an incredible opportunity to connect and interact with record-breaking attendance and representation from 52 countries. The theme of the meeting was Innovation Technology: Scaling New Heights focusing on innovative novel therapeutics, surgery, translational research, health equity research, office practice and practice during the COVID-19 pandemic. In addition to abundant scientific research, themes of eradicating racism and discrimination and promoting gender equity in our field were presented in transformational educational forums. The presidential address was delivered by Dr. Eric Topol, who discussed the utilization of artificial intelligence, “deep” data in delivering holistic, efficient, and compassionate care.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Makker V.
        • Columbo N.
        • Casado Herráes A.
        • et al.
        A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 2)
        • How J.
        • Patel S.D.
        • Fellman B.M.
        • et al.
        The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 55)
        • Barrington D.
        • Calhoun C.R.
        • Haight P.
        • et al.
        Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 56)
        • Obermair A.
        • Janda M.
        • Robledo K.
        • et al.
        Complete pathological response following levonorgestrel intrauterine device in clinically stage I endometrial adenocarcinoma: Results of a randomized clinical trial.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 72)
        • Mackay H.
        • Bender D.
        • Rimel B.J.
        • et al.
        A randomized, phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 74)
        • Kristeleit R.
        • Lisyanskaya A.
        • Fedenko A.
        • et al.
        Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase III study.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 1)
        • Matulonis U.
        • Herrstedt J.
        • Oza A.
        • et al.
        Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 37)
        • Bradley W.
        • Moore K.
        • Colombo N.
        • et al.
        Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 38)
        • Huang Q.
        • Wu X.
        • Zhu J.
        • et al.
        Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6–12 or >12 months: A subgroup analysis of the phase III NORA trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 25)
        • Yang J.
        • Wu X.
        • Zhu J.
        • et al.
        Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: A subgroup analysis of the phase III NORA trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 26)
        • Wang T.
        • Li N.
        • Tang J.
        • et al.
        Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): A multicenter, randomized, controlled, open-label, phase II trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 70)
        • Roque D.
        • Siegel E.R.
        • Buza N.
        • et al.
        Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 100)
        • Pinder L.F.
        • Muwonge R.
        • Mwanahamuntu M.H.
        • et al.
        Randomized control trial of thermal ablation of the cervix in women living with the human immunodeficiency virus in Zambia.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 4)
        • Chung H.
        • Delord J.P.
        • Perets R.
        • et al.
        Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase II KEYNOTE-158 study.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 41)
        • Frommer R.S.
        • Mileshkin L.
        • Manzyuk L.
        • et al.
        Pembrolizumab for vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 74)
        • Jazaeri A.
        • Zsiros E.
        • Amaria R.
        • et al.
        Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 40)
        • Chopra S.
        • Dora T.
        • Gupta S.
        • et al.
        Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): final analysis.
        Int. J. Radiat. Oncol. Biol. Phys. 2020; 108 (supplement, S1-S1)
        • Huang H.
        • Liu J.
        Comparative analysis of quality of life for three different adjuvant treatment modality in early stage cervical cancer: An analysis from STARS study.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 51)
        • Abt D.
        • Macharia A.
        • Hacker M.
        • et al.
        Patients with endometrial intraepithelial neoplasia do not need routine lymph node sampling.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 8)
        • Chaiken S.R.
        • Bohn J.A.
        • Bruegl A.S.
        • et al.
        Hysterectomy with a general gynecologist vs. gynecologic oncologist in the setting of complex atypical hyperplasia: A cost-effectiveness analysis.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 9)
        • Costales A.B.
        • Crane E.
        • Chambers L.
        • et al.
        Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC Trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 27)
        • Narasimhulu D.
        • Fagotti A.
        • Scambia G.
        • et al.
        Risk based triage for complex surgery in ovarian cancer: ready for prime time.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 102)
        • Handley K.
        • Sood A.K.
        • Graziela Z.
        • et al.
        Frailty repels the knife: the impact of frailty index on surgical intervention and outcomes.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 31)
        • Carneiro V.
        • Batista T.P.
        • Neto M.
        • et al.
        A proof of concept randomized phase 2 non-inferiority trial on simple versus modified radical hysterectomy in IA2-IB1 cervical cancer ≤ 2cm (LESSER).
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 60)
        • Fuh K.
        • Bookman M.A.
        • MD, Coleman RL, et al.
        Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 3)
        • Landen C.N.
        • Molinero L.L.
        • Sehouli J.
        • et al.
        Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 62)
        • Lan C.
        • He M.
        • Peng H.
        • et al.
        Genomic profiling of advanced cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 44)
        • Duska L.
        • Filiaci V.L.
        • Walker J.L.
        • et al.
        A surgical window trial evaluating medroxyprogesterone acetate with or without entinostat in endometrial cancer and validation of biomarkers of cellular response: An NRG Oncology Study.
        in: Presented at: SGO Annual Meeting. March 19–25, 2021 (Abstract 43)
        • Jones N.L.
        • Wilhite A.
        • Paladugu R.
        • et al.
        Eliminating racial disparities in endometrial cancer clinical trial enrollment in the Deep South: A pathway to equity.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 5)
        • Tabuyo A.
        • Schlumbrecht M.P.
        • Huang M.
        • et al.
        Factors associated with completion of intracavitary brachytherapy, do socio-demographic factors play a role? A pathway to equity.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 52)
        • Nasioudis D.
        • Mastroyannis S.
        • Latif N.
        • et al.
        Quality of oncologic care and outcomes of patients with endometrial cancer managed at minority serving hospitals.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 57)
        • Joshi T.V.
        • Yi M.
        • Keith S.
        • et al.
        Racial determinants of treatment delays in gynecologic malignancies.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 103)
        • Haggerty A.
        • Schumacher R.
        • Sissman L.
        • et al.
        Innovation in germline and somatic tumor testing pathways for ovarian cancer patient.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 48)
        • Carr C.
        • Bressler T.
        • Hammer M.J.
        • et al.
        Priority assessment for women with recurrent ovarian cancer: A Pilot Study.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 49)
        • Frey M.
        • Lin B.A.
        • Krinsky H.
        • et al.
        Using health information technology to improve collection of family cancer history: Prospective randomized trial of web-based tool in a gynecologic oncology outpatient clinic.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 50)
        • Rooker J.
        • Rutherford T.J.
        • Anderson M.L.
        • et al.
        Routine early screening for chemotherapy-induced hearing loss and other neuropathies in patients undergoing cancer treatment: a pilot study.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 96)
        • Davidson B.
        • Jelovsek J.E.
        • Rodriguez I.
        • et al.
        Development and validation of the gynecologic oncology predictor of postoperative opioid use (GO-POP) mode.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 95)
        • Gonzalez R.
        • Kurtovic K.
        • Habib A.S.
        • et al.
        Creation of an individualized algorithm for venous thromboembolism prophylaxis on a gynecologic oncology service.
        in: Presented at: 2021 SGO Annual Meeting. March 19–25, 2021 (Abstract 98)
        • Lara O.D.
        • Smith M.
        • Wang Y.
        • et al.
        COVID-19 outcomes of patients with gynecologic cancer in New York City: An Updated Analysis.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 33)
        • Richardson M.
        • Liang S.Y.
        • Chen T.
        • et al.
        Widening Cancer Care Disparities in the adoption of telemedicine during COVID 19 - who is left behind?.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 34)
        • Carr C.
        Does COVID-19 Compromise SGO Member Well-Being?.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 11)
        • Temkin S.
        • Hong L.J.
        • Rubinsak L.
        • et al.
        Workplace bullying, harassment and microaggressions: The results of a Women of Gynecologic Oncology (WGO) survey.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 6)
        • Li N.
        • Zhang Y.
        • Wang J.
        • et al.
        Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: A multicenter, randomized, double-blind, placebo-controlled, phase III trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 99)
        • Hardesty M.M.
        • Krivak T.
        • Wright G.S.
        • et al.
        Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 23)
        • Liu J.
        • Gaillard S.
        • Wahner Hendrickson A.
        • et al.
        An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 24)
        • Herzog T.J.
        • Pignata S.
        • Ghamande S.
        • et al.
        A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 63)
        • Hinchcliff E.
        • Patel A.
        • Fellman B.
        • et al.
        Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 64)
        • Lee J.
        • Kim J.W.
        • Kim B.G.
        • et al.
        KGOG 3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage epithelial ovarian cancer.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 65)
        • Westin S.
        • Fellman B.
        • Yuan Y.
        • et al.
        ENPAC: Phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma.
        in: Presented at: 2021 SGO Annual Meeting. March19-25, 2021 (Abstract 71)